Broad Institute

OCTOBER 4, 2023

By Allessandra DiCorato October 4, 2023 Credit: AbbVie The new small molecule inhibitor (green) sits inside the PTPN2 protein, where acidic sites are marked in red and basic sites are marked in blue. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Small Molecule 128

Small Molecule Clinical Trials Trials Engineering 128

Drug Target Review

JULY 6, 2023

1 TPD is expected to challenge undruggable proteins, which are highly difficult to target by conventional small molecules. 1 The concept of TPD was first demonstrated with a heterobifunctional small molecule to degrader a protein of interest in the early 2000s.

Targeted Protein Degradation 98

Targeted Protein Degradation Small Molecule Clinical Trials Science 98

DrugBank

MAY 15, 2024

One approach is to look beyond the traditional drug molecule. Researchers are experimenting with biologics—larger biological molecules that can do things small molecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells.

Small Molecule 98

Small Molecule Molecular Biology Drugs Disease 98

Drug Target Review

NOVEMBER 25, 2024

As the CEO of iOnctura, an innovative oncology biopharmaceutical company she co-founded in 2017, Catherine has played a key role in advancing the development of highly targeted small molecules aimed at revolutionising cancer treatment. Gender diversity is a hot topic in pharmaceutical and biotech drug development.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Strategies to Tackle PPIs Despite these challenges, some wins in targeting PPIs with small molecules have emerged.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

DrugBaron

FEBRUARY 7, 2022

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.

Small Molecule 100

Small Molecule Synthetic Chemistry Pharma Companies Pharmacokinetics 100

Drug Target Review

OCTOBER 11, 2023

Autophagy boosters, in contrast, are conventional small molecule drugs. Small molecules have been the mainstay of the pharmaceutical industry for nearly a century, they are easy to deliver – they are often given orally – and our health systems have a lot of experience of working with them.

Disease 113

Disease Treatment Small Molecule Therapies 113

The Pharma Data

NOVEMBER 19, 2020

The Company is also aiming to leverage the highly conserved structure of the SARS-CoV-2 M pro protease as a basis for the design of novel oral small molecules against predicted future variants of SARS-CoV-2 and other related human viruses.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC. Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Drug Hunter

MAY 18, 2023

Dian eventually made her way to Shanghai, where she encountered a much bigger world while earning degrees in pharmaceutical engineering and medicinal chemistry. In her small molecule DMPK research, proteomics also served to identify reactive metabolites (e.g., Dian recalls. But I didn’t want to take that as my fate.” Proteomics!

Small Molecule 131

Small Molecule DNA Pharmacokinetics Engineering 131

The Pharma Data

JANUARY 19, 2021

As part of Aptorum Group’s Acticule infectious disease platform, ALS-4 is a novel orally administered first-in-class small molecule that was developed based on an anti-virulence approach targeting Staphylococcus aureus including MRSA. About ALS-4. About Aptorum Group.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

Broad Institute

NOVEMBER 2, 2023

Our joint goal is to bring innovation to cancer patients by building a robust, sustainable pipeline in oncology,” said Dominik Ruettinger, Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG.

Therapies 105

Therapies Research Small Molecule Clinical Trials 105

Drug Patent Watch

DECEMBER 13, 2023

The small molecule drug covered by this patent is AMITIZA. Takeda Pharmaceutical Company… The post New patent lawsuit: Walgreen CO v. Takeda Pharmaceutical Company Limited – Drug patent: 7,795,312 appeared first on DrugPatentWatch - Make Better Decisions. A new lawsuit citing drug patent 7,795,312 has been filed.

Pharmaceutical Companies 45

Pharmaceutical Companies Small Molecule Pharmaceuticals Drugs 45

Drug Patent Watch

DECEMBER 13, 2023

The small molecule drug covered by this patent is AMITIZA. Takeda Pharmaceutical Company… The post New patent lawsuit: Walgreen CO v. Takeda Pharmaceutical Company Limited – Drug patent: 8,779,187 appeared first on DrugPatentWatch - Make Better Decisions. A new lawsuit citing drug patent 8,779,187 has been filed.

Pharmaceutical Companies 45

Pharmaceutical Companies Small Molecule Pharmaceuticals Drugs 45

FDA Law Blog: Biosimilars

SEPTEMBER 11, 2024

One specific kind of nitrosamines called N-nitrosamine drug substance-related impurities, or NDSRIs, are especially vexing to FDA and to industry because they mimic the structure of the specific active pharmaceutical ingredients (API), making them difficult to detect. It’s these varied scenarios that give quality managers nightmares.

Small Molecule 105

Small Molecule FDA Production Drugs 105

Drug Target Review

OCTOBER 23, 2024

Technologies for the rapid and efficient testing of small molecules and biologics have greatly accelerated drug discovery. However, many pharmaceutically relelvant targets remain ‘undruggable’. 2024 Jun 14;384(6701):1259–65.

Small Molecule 64

Small Molecule DNA Drugs Pharmaceuticals 64

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Drug Target Review

NOVEMBER 1, 2023

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We have several exciting projects in various stages of discovery, but a small-molecule drug that is causing a lot of excitement at the moment is Capivasertib.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

The Premier Consulting Blog

NOVEMBER 20, 2024

Process validation is a critical regulatory requirement in pharmaceutical manufacturing. In the case of urgent or immediate public interest, process validation may be conducted concurrently with manufacturing the commercial small molecule or biologic product to expedite product availability for patients.

Small Molecule 52

Small Molecule Drugs FDA Production 52

Drug Target Review

AUGUST 25, 2023

However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. References Oronsky B, Scribner C, Aggarwal R, Cabrales P.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

JANUARY 5, 2021

Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech , a Roche company, to identify and advance novel RNA-targeted small molecule therapeutics. This is because many proteins do not have small-molecule binding sites. This is not the first deal for RNA therapeutics for Genentech.

RNA 52

RNA Small Molecule DNA Licensing 52

The Pharma Data

NOVEMBER 22, 2020

SAN DIEGO–( BUSINESS WIRE )– Vividion Therapeutics , a biotechnology company discovering and developing selective small molecule medicines that drug traditionally inaccessible targets, today announced that Jeffrey Hatfield has been appointed as the company’s chief executive officer. 23, 2020 13:30 UTC.

Small Molecule 52

Small Molecule Pharmacy Pharmaceuticals Science 52

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Dark Matter Blog

JANUARY 16, 2023

Our terra firma is small-molecule medicines. As we know, small molecules have been the mainstay of our pharmacopeia for several centuries and have, almost without exception, targeted proteins. This is why Arrakis set out in 2015 on an expedition to figure out how to develop small molecules that can target RNA.

Small Molecule 52

Small Molecule RNA Drugs Disease 52

Sygnature Discovery

APRIL 18, 2023

Sygnature Discovery is pleased to have entered into a research collaboration agreement with the global healthcare group Daewoong Pharmaceutical to accelerate the discovery of a novel small molecule to target autoimmune disease.

Small Molecule 52

Small Molecule Computational Chemistry Research Science 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc. About Eloxx Pharmaceuticals. Eloxx Pharmaceuticals, Inc. Eloxx’s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. SOURCE: Eloxx Pharmaceuticals, Inc.

Pharmaceuticals 52

Pharmaceuticals RNA Small Molecule Protein Production 52

The Pharma Data

JANUARY 31, 2021

.–( BUSINESS WIRE )– Indication BioScience, an early-stage pharmaceutical development company focused on identifying, developing, and commercializing innovative therapies to address unmet needs in cardiovascular health, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S.

Small Molecule 52

Small Molecule Therapies Clinical Research Pharmaceuticals 52

The Pharma Data

DECEMBER 10, 2020

11, 2020 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. LX9211 is a potent, orally delivered, selective small molecule inhibitor of adapter-associated kinase 1 (AAK1). About Lexicon Pharmaceuticals. THE WOODLANDS, Texas, Dec. Nasdaq: LXRX), announced today that it has received Fast Track designation from the U.S.

FDA 52

FDA Pharmaceuticals Small Molecule Clinical Development 52

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

Drug Target Review

MARCH 28, 2024

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In short, this hypothesis underscores the potential benefits of aligning pharmaceutical development more closely with nature.

Production 128

Production Drugs Small Molecule Bioinformatics 128

The Pharma Data

OCTOBER 15, 2020

Vertex Pharmaceuticals has decided to give up on its experimental VX-814, a small molecule drug for the rare genetic disease Alpha-1 antitrypsin deficiency (AATD), canning the drug’s development after seeing lackluster results from an early phase 2 trial. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein is a leading global research and development-based pharmaceutical company headquartered in Japan.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

Drug Target Review

DECEMBER 6, 2023

We also relay the application of a high-throughput assay to screen for potential small molecule inhibitors of SARS-CoV-2 replication, underscoring the ongoing efforts to combat the global pandemic.

Small Molecule 59

Small Molecule Therapies Pharmaceuticals Disease 59

Agency IQ

NOVEMBER 10, 2023

BY ALEXANDER GAFFNEY, MS, RAC | NOV 9, 2023 6:35 PM CST Background on CDER’s Office of Pharmaceutical Quality (OPQ) CDER’s Office of Pharmaceutical Quality became operational in January 2015, making it a still relatively recent addition to the agency. Read our analysis of a recent meeting focused on KASA here. ]

Pharmaceuticals 40

Pharmaceuticals Small Molecule Science FDA 40

Metabolite Tales Blog

FEBRUARY 15, 2024

Senior Purification Chemist Hypha Discovery has an exciting opportunity for an experienced purification chemist to join our team to work on metabolite synthesis and impurity purification projects with our global pharmaceutical and agrochemical partners. The role is predominantly lab-based.

Small Molecule 52

Small Molecule Laboratories Production Pharmaceuticals 52

FDA Law Blog: Biosimilars

JULY 24, 2024

Each fall, leading pharmaceutical patent litigators for brand-name and generic drug companies gather at the Paragraph IV Disputes Master Symposium in Chicago to receive up-to-the-minute information on the latest developments affecting Hatch-Waxman litigation and participate in significant peer-to-peer networking opportunities.

Small Molecule 52

Small Molecule Clinical Trials FDA Pharmaceuticals 52